Stay ahead in the booming mRNA market, projected to reach $63.28 billion by 2025, with the 3 rd mRNA Process Development & Manufacturing Summit 2025 - Europe’s premier industry-focused forum dedicated ...

From global vaccines to personalized cancer therapies, mRNA is being considered across several clinical applications, which ultimately creates varying requirements in terms of production scale and ...

Learn from the MHRA about evolving CMC expectations, submission criteria, and initiatives for streamlining approval routes for mRNA platforms. Continuous processing: Optimizing efficiency & ...

- Co-Hosts Seminar with mRNA CDMO Kudo Bio to Demonstrate Linea IVT Capability for Rapid mRNA Manufacturing - STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc.

In vitro-transcribed mRNAs have been proven efficient in various therapeutic applications. However, manufacturing them poses challenges due in part to complexity of the molecules as well as the ...

The market for mRNA vaccines has experienced a surge fueled by the global rollout of the COVID-19 vaccines, and the potential of mRNA technology in public health opens a new frontier in medical ...

The global mRNA synthesis and manufacturing market is projected to grow at a compound annual growth rate of approximately 6% during the forecast period, reflecting the expanding role of mRNA ...

RIO RANCHO, N.M.--(BUSINESS WIRE)--Nature’s Toolbox (NTx), a life sciences company developing next-generation platforms for RNA and protein manufacturing, today launched NTx Services. This new service ...

A new study shows lipid nanoparticles can be formulated at much higher lipid concentrations using a modular mixing approach, improving in vivo performance, stability, and scalability.

LineaRx will present its Linea™ IVT platform - a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase (Linea™ RNAP) - as a ...

STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced its participation at upcoming mRNA ...